Camurus AB (CAMRF)
64.00
0.00 (0.00%)
USD |
OTCM |
Aug 26, 16:00
Camurus Net Income (Quarterly) : 25.72M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 25.72M |
| March 31, 2026 | 15.73M |
| December 31, 2025 | 10.72M |
| September 30, 2025 | 20.24M |
| June 30, 2025 | 25.34M |
| March 31, 2025 | 18.48M |
| December 31, 2024 | 13.63M |
| September 30, 2024 | 12.41M |
| June 30, 2024 | 6.941M |
| March 31, 2024 | 7.490M |
| December 31, 2023 | -1.425M |
| September 30, 2023 | 7.991M |
| June 30, 2023 | 28.59M |
| March 31, 2023 | 5.635M |
| December 31, 2022 | 1.218M |
| September 30, 2022 | 3.317M |
| June 30, 2022 | 0.8365M |
| March 31, 2022 | -0.0805M |
| December 31, 2021 | -1.582M |
| September 30, 2021 | -0.7131M |
| June 30, 2021 | -5.752M |
| March 31, 2021 | -2.603M |
| December 31, 2020 | -7.602M |
| September 30, 2020 | -2.287M |
| Date | Value |
|---|---|
| June 30, 2020 | -2.062M |
| March 31, 2020 | -6.358M |
| December 31, 2019 | -7.471M |
| September 30, 2019 | -6.542M |
| June 30, 2019 | -9.276M |
| March 31, 2019 | -7.370M |
| December 31, 2018 | -9.635M |
| September 30, 2018 | -4.891M |
| June 30, 2018 | -7.776M |
| March 31, 2018 | -4.470M |
| December 31, 2017 | -6.273M |
| September 30, 2017 | -6.43M |
| June 30, 2017 | -5.206M |
| March 31, 2017 | -4.511M |
| December 31, 2016 | -3.072M |
| September 30, 2016 | -1.551M |
| June 30, 2016 | -2.501M |
| March 31, 2016 | -2.295M |
| December 31, 2015 | -3.747M |
| September 30, 2015 | -2.680M |
| June 30, 2015 | -13.69M |
| March 31, 2015 | 1.225M |
| December 31, 2014 | 10.08M |
| September 30, 2014 | -0.2237M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Orexo AB | -10.95M |
| Swedencare AB | 2.531M |
| Moberg Pharma AB | -0.3504M |
| Infant Bacterial Therapeutics AB | -2.509M |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 74.97M |
| Total Expenses (Quarterly) | 49.26M |
| EPS Diluted (Quarterly) | 0.432 |
| Enterprise Value | 3.399B |
| Gross Profit Margin (Quarterly) | 92.70% |
| Profit Margin (Quarterly) | 34.30% |
| Earnings Yield | 1.89% |
| Operating Earnings Yield | 2.33% |
| Normalized Earnings Yield | 1.888 |